Corbus Pharmaceuticals Holdings, Inc. (LON:0SZI)

Market Cap	106.50M +13.0%
Revenue (ttm)	n/a
Net Income	-50.22M
EPS	-4.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,104
Average Volume	1,695
Open	7.40
Previous Close	7.44
Day's Range	7.28 - 7.77
52-Week Range	4.63 - 24.50
Beta	2.78
RSI	40.66
Earnings Date	Mar 12, 2026

About LON:0SZI

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2009
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0SZI

Financial Performance

Financial numbers in USD